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BACKGROUND Low ﬂow, low gradient, aortic stenosis is becoming
increasingly recognized as a subgroup of severe aortic stenosis. Ac-
celeration time (AT) has been correlated with severity of severe aortic
stenosis (AS). We examined the epidemiology of Low ﬂow, low
gradient (LF/LG) severe AS and the correlation with AT to predict the
valve area.
METHODS We studied 138 consecutive patients diagnosed with se-
vere AS and normal ejection fraction (>55%) by echocardiography.
The mean age was 8110 yrs; 66% were females, 63% were African
Americans and 86% had hypertension. Chi square test was used for
comparing binary variables; student t-test for comparing means, and
linear regression was performed using IBM SPSS.
RESULTS 47 (34%) patients had stroke volume index < 35 and 28
(20%) had low ﬂow and low aortic mean gradient (<40 mmHg). There
were no signiﬁcant differences in gender and race distribution or past
medical history in the groups divided based on LF/LG. The aortic
valve area by continuity equation was 0.740.16 vs 0.730.14, nor
was there a difference in AVA index, dimensionless index or EF. Mean
gradient (4516 vs 27.57 mmHg), as did peak gradient (7323 vs
4812 mmHg), stroke volume index (42.410 vs 285 ml/m2), ZVA
(4.31.4 vs 5.41.8), average AT (11320 vs 9416 ms) and average
ejection time (31631 vs 29237 sec) were signiﬁcantly different (p
value <.01). AT signiﬁcantly and negatively correlated with AVA index
in both the LF/LG (r -0.368, p <.01), and rest of the cohort group (r
-0.414, p <.01). Adjusted for age, gender, race, and ejection fraction
using linear multivariate regression analysis, AT and LF/LG were
signiﬁcant predictors of AVA index.Parameter Coefﬁcient SE P Value(Constant) .603 .047Female .044 .017 <.01Acceleration time(AT) -1.913 .402 <.01LF/LG -.068 .021 <.01CONCLUSIONS Acceleration time is signiﬁcantly correlated with AVA
index derived from the continuity equation in both traditional severe
AS and in LF/LG severe AS, and is an independent predictor of AVA
index. The utility of AT in differentiating the severe from moderate AS
in LF/LG group needs to be evaluated.
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BACKGROUND A percutaneous approach with transcatheter aortic
valve replacement (TAVR) and percutaneous coronary intervention
(PCI) of the left main (LM) is frequently utilized in high-risk patients
with coexisting aortic stenosis and LM disease. Outcomes of TAVR
plus LM PCI (Figure 1A) have not been previously reported. The pri-
mary objective of the TAVR-LM registry is to evaluate the clinical
outcomes in patients undergoing TAVR plus LM PCI.
METHODS We retrospectively collected clinical, echocardiographic,
computed-tomographic and angiographic characteristics in 204 pa-
tients undergoing TAVR plus LM PCI. One-hundred twenty-eight
matched patient pairs were generated by performing 1:1 case-control
matching between 167 patients with pre-existing LM stent undergoing
TAVR and 1188 control patients undergoing TAVR without LM
revascularization.
RESULTS One-year mortality (9.4% vs. 10.2%, p ¼ 0.83) was similar
between the TAVR plus LM PCI cohort and matched controls
(Figure 1B). One-year mortality after TAVR plus LM PCI was not
different among patients with unprotected, compared to protected
LM (7.8% vs. 8.1%, p ¼ 0.88); among those with ostial versus non-
ostial LM stents (10.3% vs. 15.6%, p ¼ 0.20); and among those un-
dergoing LM PCI within 3 months, compared to those with LM PCI
greater than 3 months prior to TAVR (7.4% vs. 8.6%, p ¼ 0.61). Un-
planned LM PCI performed due to TAVR-related coronary complica-
tion, compared to planned LM PCI performed for pre-existing LM
disease, resulted in increased 30-day (15.8% vs. 3.4%, p ¼ 0.013) and 1-
year mortality (21.1% vs. 8.0%, p ¼ 0.071).
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to the LM coronary artery, TAVR plus LM PCI is safe and technically
feasible, with short- and intermediate-term clinical outcomes com-
parable to patients undergoing TAVR alone. Our results suggest that
TAVR plus LM PCI is a reasonable option for patients who are at high
risk for surgery.
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BACKGROUND The size of the transcatheter heart valves (THV) is
overestimated up to 20% based on aortic annulus diameter measured
using computed tomography (CT). However, the prosthesis may not
be fully expanded during implantation. THV underexpansion might
have detrimental clinical consequences. The aim of this study was to
deﬁne the degree of underexpansion degree of different THVs,
introduced as the shrinking index, and its predicting role in pace-
maker implantation after transcatheter aortic valve implantation
(TAVI).
METHODS We enrolled 112 patients (68 men, 798 years old) who
underwent TAVI with the self-expanding CoreValve (n¼28), me-
chanically expanded Lotus valve (n¼ 35) or balloon expandable
Edwards SAPIEN XT (n¼18) and Edwards SAPIEN 3 (n¼ 31). The cover
index of the THV was calculated as the percentage difference of the
nominal prosthesis size and annulus diameter measured using CT.
Intraprocedural transesophageal echocardiography (TEE) was per-
formed to determine the size of the THV inﬂow after implantation.
The shrinking index was calculated as the percentage of the difference
between the inﬂow size by TEE and the nominal prosthesis size
divided by prosthesis size. After excluding the patients with baseline
pacemaker (n¼7) and patients deceased within 24 hours after TAVI
(n¼4), the role of the shrinking index for pacemaker implantation
within 30 days was investigated.
RESULTS Cover index per CT assessment was 187% for CoreValve,
24% for Lotus, 95% for Edwards SAPIEN and 45% for Edwards
SAPIEN 3 (ANOVA p<0.001, Corevalve was signiﬁcantly larger than
the others). Compared with aortic annulus diameter measured using
TEE in long axis view, the overestimation increased to 289% for
CoreValve, 128% for Lotus, 1812% for Edwards SAPIEN and 128%
for Edwards SAPIEN 3 (ANOVA p<0.001, Corevalve was signiﬁcantly
larger than the others). Conversely, the shrinking index after TAVI
was -306% for CoreValve, -205% for Lotus, -226% for SAPIEN XT
and -195% for SAPIEN 3 (ANOVA p<0.001, Corevalve was signiﬁ-
cantly larger than the others). The interobserver variability (relative
difference) of TEE in measuring the aortic annulus and prosthesis
inﬂow was 65% and 75% respectively. Using a cut-off value of -22%
of the shrinking index, the pacemaker implantation rate was of
borderline difference between patients with shrinking index lower
than -22% (pacemaker implantation rate 65%) and those higher than
-22% (35%) (univariate analysis p¼0.06). However, there was no sig-
niﬁcant difference within each type of THV.
CONCLUSIONS The shrinking index determines the degree of THV
underexpansion after TAVI and can be reliably measured with TEE.
The self-expanding CoreValve tended to be under-expanded the
most, indicated by the largest shrinking index. THV with a shrinking
index larger than 22% tended to predict higher pacemaker implanta-
tion rate after TAVI. Its deﬁnite predicting role needs further study
with larger patient population and more covariables included.
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BACKGROUND Mutidetector cardiac computed tomography (MDCT)
is the gold standard for aortic annular sizing in transcatheter aortic
valve replacement (TAVR). Balloon sizing is increasingly used in pa-
tients when there remains a discrepancy in preoperative assessment
for the most appropriate valve size that should be utilized. A com-
parison between balloon and MDCT sizing has not been reported.
METHODS We retrospectively reviewed 205 patients undergoing
balloon-expandable TAVR who underwent preoperative annular
MDCT or intraoperative balloon sizing. Baseline characteristics and
30-day outcomes are compared between groups. Logistic regression
modules were used to compare paravalvular leak (PVL) rates adjusting
for access site (TF or non-TF), valve type (SAPIEN or SAPIEN XT), size
(23, 26, or 29), and valve calciﬁcation.
RESULTS 205 patients underwent TAVR with MDCT (n¼110) or
balloon sizing (n¼95). Balloon sized patients were older (83 vs. 81
years, p¼0.03), with more valve calciﬁcation (60.2% vs. 30.9%,
p<0.001), and underwent more minimalist TAVR (61.1% vs. 40%,
p¼0.03). Balloon-sized patients also received less 29 mm valves (9.5%
vs. 29.1%, p¼0.001) and more intraprocedural balloon valvuloplasties
(2 vs. 1, p¼0.001), ﬂuoroscopy time (25.6 vs. 20.3 min, p¼0.001), and
intra-procedural contrast (130.0 vs. 108 mL, p¼0.01). Though we
found no difference between balloon and MDCT sizing in rates of
acute renal failure, annular rupture, and  mild PVL by angiography
or 30-day TTE; balloon sized patients had a higher aortic regurgitation
index (Table 1). 30-day rates of  moderate PVL were 7.0% with
balloon and 5.7% with MDCT sizing (p¼0.34). Balloon sizing recom-
mended a different valve size in 34% patients that underwent both
sizing methods (n¼50).
